Latest / Stock Movers / Meta Gains on Settlement, Nvidia Dips Ahead of Earnings, RevMed Rallies
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio, news. The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg data.
- 0:15Speaker 2: I'm Tim Stenevek, along with Lisa Mateo. Let's take a
- 0:20Speaker 2: look at some stocks on the move. We are joined
- 0:22Speaker 2: by Bloomberg News cross-asset reporter, Danica Seikova. Hey, Danica.
- 0:25Speaker 1: Hey. Hi there.
- 0:26Speaker 3: Let's talk about Meta. Meta agreed to pay up to
- 0:30Speaker 3: 18 billion in landmark settlements to multiple U.S. states, saying
- 0:35Speaker 3: that the company deliberately designed Facebook and Instagram to encourage
- 0:39Speaker 3: compulsive use among younger people.
- 0:42Speaker 2: Users.
- 0:42Speaker 3: This is just an incredible case. Through its start until now,
- 0:46Speaker 3: everyone has been following it. It's very interesting that if
- 0:50Speaker 3: this case was resolved and it posed such enormous risk
- 0:55Speaker 3: for Meta, the company itself, estimated that it's going to
- 0:58Speaker 3: cost as much as $ 1. 4 trillion. Just historic case. I
- 1:02Speaker 3: don't think anything like this has happened like that before. Obviously,
- 1:05Speaker 3: this is the settlement we have as part of the deal.
- 1:07Speaker 3: The company will put new guardrails. A lot of things
- 1:10Speaker 3: will change. But compared to what could have happened, obviously,
- 1:13Speaker 3: the changes are much smaller. We're seeing an interesting reaction. Initially,
- 1:16Speaker 3: the stock sold off. Now it's actually up more than 1.5%.
- 1:20Speaker 3: That said, we see a lot of pressure in the
- 1:22Speaker 3: social media companies, Pinterest, Reddit, Snapchat. All of those companies
- 1:27Speaker 3: are definitely feeling the pressure. We've seen more and more
- 1:29Speaker 3: governments talk about this. A lot of European countries are
- 1:32Speaker 3: talking more and more about regulating social media for younger users.
- 1:35Speaker 3: So who knows if this case is just the start
- 1:37Speaker 3: of a broader debate. But I think it's kind of
- 1:40Speaker 3: interesting that the initial reaction faded away.
- 1:42Speaker 1: So fast.
- 1:43Speaker 3: I guess the price tag of the actual lawsuit was
- 1:47Speaker 3: much higher, so investors felt some relief, but it's really
- 1:49Speaker 3: surprising to me.
- 1:50Speaker 1: And how about Nvidia?
- 1:51Speaker 3: Of course, we've been talking about it all day right now,
- 1:55Speaker 3: waiting for those results to come in ahead of it.
- 1:57Speaker 1: Well, they're down about 1%, just about.
- 1:59Speaker 2: So what other details do you have for us?
- 2:01Speaker 3: Everyone is waiting for NVIDIA's earnings. Obviously, it's not about
- 2:05Speaker 3: one company. It's about the AI trade. It's about the economy.
- 2:07Speaker 3: It's about everything. It's about that. So indeed, the stock
- 2:12Speaker 3: is down about 1%. The results we're expecting is another
- 2:14Speaker 3: quarter of strong results. Analysts project the revenue to nearly
- 2:18Speaker 3: double from a year ago, similar number for income. The
- 2:22Speaker 3: revenue number is the fastest pace in two years. But nevertheless,
- 2:26Speaker 3: this can still be a big disappointment for investors, even
- 2:29Speaker 3: if they reach those numbers. Investors, they're looking for capital spending.
- 2:35Speaker 3: They're looking for future demands. We've been talking a lot
- 2:38Speaker 3: about rising costs. People say that AI chips will rise
- 2:41Speaker 3: more than ever. 15% in some cases, surging memory costs.
- 2:45Speaker 3: So I feel so investors may be quite sensitive about
- 2:48Speaker 3: those metrics, even if earnings come just as expected, even
- 2:51Speaker 3: if it's another amazing That said, the company is up
- 2:53Speaker 3: about 13%, which compared to previous years is not such
- 2:56Speaker 3: a strong rally. So definitely investors are not as forgiving
- 2:59Speaker 3: as in the past.
- 3:00Speaker 2: I mean, it's a $ 5. 1 trillion company. True.
- 3:02Speaker 3: 13%, I'll take it.
- 3:05Speaker 2: You started with Meta. That's just shy of $ 1. 5 trillion,
- 3:10Speaker 2: just for context of other Mag7. Exactly.
- 3:13Speaker 3: Massive company. So 13% is enough.
- 3:15Speaker 2: Pretty massive.
- 3:15Speaker 3: Compared to previous years, still.
- 3:17Speaker 2: All right, what's the next one you got for us?
- 3:19Speaker 3: We have Revolution Medicines. Really great news for investors and society.
- 3:25Speaker 3: Revolution Medicines won U.S. approval for a breakthrough pill that
- 3:29Speaker 3: lengthens the lives of patients with advanced pancreatic cancer. I
- 3:33Speaker 3: feel as though there has been a lot of advancements
- 3:35Speaker 3: in that, and investors were kind of expecting it. The
- 3:38Speaker 3: ticker is RTVM. The stock is getting just a small
- 3:42Speaker 3: boost today, but if you look at the chart up
- 3:44Speaker 3: to date, the company is valued at more than $ 46 billion,
- 3:49Speaker 3: and it has more than doubled since April. So, you know,
- 3:52Speaker 3: obviously the reaction was going into this.
- 3:54Speaker 2: We've spoken about this drug in the past. It's going
- 3:56Speaker 2: to be a list price of more than $ 475, 000 a year.
- 3:57Speaker 2: That's very expensive. Yeah. Here's what's notable to me, though.
- 4:03Speaker 2: The current standard of treatment, patients lived in the trial
- 4:05Speaker 2: for 6.7 months, while those who received this drug survived
- 4:09Speaker 2: for more than 13 months. So it still is such
- 4:12Speaker 2: a short period of time when you're diagnosed with this.
- 4:14Speaker 3: Yes, but they doubled it.
- 4:15Speaker 2: They doubled it, exactly.
- 4:16Speaker 3: No, it's a very complicated case, because from what I understand,
- 4:19Speaker 3: this is often diagnosed very late compared to other cancers.
- 4:22Speaker 3: And also, these treatments allow people to stay at home
- 4:25Speaker 3: and be with their families compared to other treatments. So
- 4:27Speaker 3: still a great relief and great progress going forward.
- 4:30Speaker 2: Denit Zasekova with today's Stock Movers.
- 4:34Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:38Speaker 1: us throughout the day for the latest roundup of companies
- 4:41Speaker 1: making news on Wall Street. And for the latest market
- 4:44Speaker 1: moving headlines, listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:50Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:53Speaker 1: Business app.